TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00223678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Rapamycin will start within 24 hours of last calcineurin inhibitors (Cya, Prograf). Initial dose of Rapamune 10mg will be given for 3 days and then dose will be adjusted to attain a target whole blood trough of 5-15
Study: NCT03674125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-6150
Description: Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-6150
Description: Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-6150
Description: Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-6150
Description: Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection)
Study: NCT06220903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex Decongestive Therapy
Description: 1. Manual Lymph Drainage: Cervical region lymph drainage and abdominal region lymph drainage (especially combined with abdominal breathing) were applied.~2. Skin Care: Moisturizing creams with a pH of 5.5 were applied to the extremities before bandaging.~3. Multilayer Bandaging: Short pull bandage application was applied in a gradient manner.~4. Exercise: Joint range of motion exercises, breathing exercises (abdominal breathing), decongestive exercises, and self-drainage techniques were taught.~5. Compression Stocking: After the decongestion phase was over, flat knit compression stockings were recommended according to the patient's extremity.
Study: NCT02824263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP withdrawal
Description: CPAP is discontinued for 3 nights.
Study: NCT00373750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Family Spirit Intervention
Description: The Family Spirit Intervention was developed over a decade through community-based participatory research.The intervention content included 43 structured lessons and followed a culturally congruent format.
Study: NCT02928107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-HS
Description: Patients will be given information on the Tele-HS and given access to take the screening at home or in-office, depending on arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-HS
Description: Patients will be given information on the Tele-HS and given access to take the screening at home or in-office, depending on arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-HS
Description: Patients will be given information on the Tele-HS and given access to take the screening at home or in-office, depending on arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCP encouragement
Description: Patients will or will not either receive PCP encouragement to do the Tele-HS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCP encouragement
Description: Patients will or will not either receive PCP encouragement to do the Tele-HS.
Study: NCT03739437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Contingency Management
Description: Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and incentives that are not contingent on smoking abstinence (incentives are yoked to participants in the contingency management group).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and incentives that are not contingent on smoking abstinence (incentives are yoked to participants in the contingency management group).
Study: NCT04586582

Intervention type: DIAGNOSTIC_TEST
Intervention: ST-segment resolution <40.15%
Description: Forty-two STEMI patients with single-branch coronary artery stenosis or occlusion were enrolled. ST-segment elevations were measured at emergency admission and at 24 h after PCI. Late gadolinium-enhanced cardiac magnetic resonance imaging (CMR-LGE) was performed 7 days after PCI to evaluate myocardial scars.

Intervention type: DIAGNOSTIC_TEST
Intervention: ST-segment resolution <40.15%
Description: Forty-two STEMI patients with single-branch coronary artery stenosis or occlusion were enrolled. ST-segment elevations were measured at emergency admission and at 24 h after PCI. Late gadolinium-enhanced cardiac magnetic resonance imaging (CMR-LGE) was performed 7 days after PCI to evaluate myocardial scars.
Study: NCT00145925

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perindopril-indapamide

Intervention type: DRUG
Group type: OTHER
Intervention: Gliclazide MR-based glucose lowering
Study: NCT00359190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: GW572016 ditosylate salt (lapatinib) will be given as 250 mg tablets via oral route
Study: NCT01487356

Intervention type: OTHER
Intervention: No intervention
Description: Colonoscopies were conducted as per the endoscopist's usual practice. No change in protocol was expected.
Study: NCT01959048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Study: NCT01220232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir/Lamivudine
Description: Abacavir/Lamivudine 600/300 mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine
Description: Abacavir/Lamivudine 600/300 mg QD for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: Lersivirine 750 mg QD for 10 days
Study: NCT02905760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Furosemide: Special LASILIX (250 mg/25 ml) solution for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo filling
Description: Placebo filling: Glucose 5%, 500mL infused over 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo furosemide
Description: Placebo furosemide: glucose 5% for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vascular filling
Description: Vascular filling: Sodium 0.9% 500mL infused over 30 minutes.
Study: NCT03528863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness Meditation
Description: Receive web-based mindfulness meditation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03587857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health Application
Description: This mobile health app is a modular, adaptive, and personalized intervention delivered via a mobile phone. It is grounded in the Information Motivation Behavioral Skills (IMB) model. It was created in collaboration with YLWH (18-29 years-old) using a Human-Centered Design approach to help improve engagement in HIV care among this age group.
Study: NCT00528892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: switching PI to raltegravir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: boosted PI
Description: continue on boosted-PI
Study: NCT03200340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: Oral administration of EC-18 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: Oral administration of EC-18 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: Oral administration of EC-18 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: Oral administration of EC-18 twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match EC-18 capsule administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match EC-18 capsule administration
Study: NCT03186196

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet containing Folate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet containing Folate
Study: NCT01163721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine ER 1000 mg (two 500 mg tablets) administered orally twice daily
Study: NCT01544010

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced TTM+Addiction Tailored Feedback Report
Description: Tailored print feedback report based on assessment of Addiction level (# cigarettes/day),Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
Study: NCT03763838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Six weeks of daily self-administered relaxing acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. These are points that are recognized as effective in Traditional Chinese Medicine (TCM).
Study: NCT01163721

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ranolazine administered orally twice daily
Study: NCT04612387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body therapy
Description: Online yoga, meditation and nutrition tips.
Study: NCT01295281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric POBE 2.0
Description: To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric POBE 2.0
Description: To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric PVC
Description: To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric PVC
Description: To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
Study: NCT03475017

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Supplement A
Description: The patients will receive 3 capsules per day containing 500mg of curcumin and 5mg of piperine for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Supplement B
Description: The patients will receive 3 capsules of placebo per day containing 500mg of maize starch for 4 weeks
Study: NCT03189043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antimicrobial Surface
Description: Antimicrobial Surface
Study: NCT04029935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Fatigue
Description: Maximal cycling effort for 30s (Wingate modified)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: time-matched task (sitting on the bike without pedalling)
Study: NCT01507558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Administration of dexamethasone to SFA/popliteal adventitia
Description: Following a balloon angioplasty or atherectomy of a stenotic TASC II A, B, or C lesion in the superficial femoral or popliteal artery, a Bullfrog Micro-Infusion Catheter will be used to infuse 0.96 mg dexamethasone per cm arterial lesion.
Study: NCT01928498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Eluting Balloon Angioplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Study: NCT03171831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan（4 mg/kg/day,4 days）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide（50 mg/kg/day,4 days）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine（50 mg/m2/day,3 days）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil（0.25g/day）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus（0.03mg/kg/day）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Thymoglobulin（2.5 mg/kg/day,4 days）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Basiliximab（10mg on day 0 and +4）
Study: NCT00835120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
Study: NCT01389765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally
Study: NCT00713726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FentanyL
Description: Fentanyl: 1 µg/kg/h for preterm infants and 2 µg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Tramadol: 0.1 mg/kg/h for preterm infants and 0.2 mg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
Study: NCT00753051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clozapine+haloperidol
Description: clozapine 300-900 mg/d haloperidol 4-60 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clozapine,electroconvulsive therapy
Description: clozapine 300-900 mg/d electroconvulsive therapy 4-12 times
Study: NCT03474471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Following a PR program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Following a PR program

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBV treatment
Description: Bronchoscopic lung volume reduction using endobronchial valves (EBV)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBV treatment
Description: Bronchoscopic lung volume reduction using endobronchial valves (EBV)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBV treatment
Description: Bronchoscopic lung volume reduction using endobronchial valves (EBV)
Study: NCT00771563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin + docetaxel
Description: docetaxel 75 mg/m2 d1 and cisplatin 75mg/m2 d1 (q 3wks for 4 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin + docetaxel + enoxaparin
Description: cisplatin 75 mg/m2 d1 and docetaxel 75 mg/m2 d1 (q 3 wks for 4 cycles) + daily enoxaparin 1mg/kg/d sc
Study: NCT00081874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Phase I: Starting dose 5 mg by mouth daily for 28 days.~Phase II: Maximum Tolerated Dose (MTD) from Phase I.
Study: NCT04484831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABT Weight Loss Intervention
Description: This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Care
Description: This includes 15 handouts on elements of a healthy lifestyle and a midpoint one-on-one nutrition consultation with a registered dietitian.
Study: NCT03040622

Intervention type: DEVICE
Intervention: WATCHMAN Left Atrial Appendage Closure
Description: WATCHMAN Left Atrial Appendage Closure
Study: NCT03861819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity interval training (VIIT)
Description: Subjects will be fitted with a heart rate monitor around the chest and a baseline 4ml blood sample will be drawn. Vigorous intensity interval training will correspond to heart rate (HR) range of 80-90% of heart rate at age-predicted heart rate maximum (220-age). After approximately 5 minutes of warmup subjects will perform 10 intervals of VIIT: 30 seconds of vigorous intensity exercise followed by 60 seconds of rest. Rated Perceived Exertion (RPE) will be rated by 15-point Borg scale; should correspond to HR/10 at end of each interval. The subject will self-adjust the intensity of the exercise bouts and will be encouraged by the researcher to achieve the desired intensity. The exercise session will finish with a short cool-down period and will last no more than 25 minutes in total. A 4ml blood sample will be drawn immediately following the exercise session and 2-hours after exercise cessation.
Study: NCT02750150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freezed-dried plasma
Description: early transfusion of 4 units of freezed dried plasma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fresh-frozen plasma
Study: NCT03565731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-PA
Description: The overall goal of the intervention is to increase bout-related moderate-to-vigorous physical (MVPA) activity to greater than 200 minutes per week. The basic structure is an initial on-site, group-based intervention workshop, written materials, weekly emails, and monthly phone calls for a total of 3 months.
Study: NCT01972711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-36385625 as a single oral dose of 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: Amisulpride as a single oral dose of 400 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose placebo
Study: NCT02110147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: uridine triacetate
Study: NCT01793220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reminder
Description: A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
Study: NCT03279133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir 90mg/Sofosubvir 400mg
Description: Ledipasvir 90mg/Sofosubvir 400mg (LDV/SOF) FDC is to be administered once daily with or without food for12 weeks.
Study: NCT04555538

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: These are routinely performed for many cardiac conditions, including atrial arrhythmias. The adverse effects are small but include claustrophobia and metallic objects. Therefore all patients will be counselled prior to the scans by an experienced MRI practitioner and standard measures will be taken to avoid distress during the scan. Furthermore, patients will be screened using routine clinical protocols in order to avoid any harm due to interaction of the MRI scanner with metallic objects.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: These are routinely performed for many cardiac conditions, including atrial arrhythmias. The adverse effects are small but include claustrophobia and metallic objects. Therefore all patients will be counselled prior to the scans by an experienced MRI practitioner and standard measures will be taken to avoid distress during the scan. Furthermore, patients will be screened using routine clinical protocols in order to avoid any harm due to interaction of the MRI scanner with metallic objects.
Study: NCT01833715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine group,receive morphine 0.08 mg / kg at the start of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone group,receive methadone 0.08 mg / kg at the start of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVA
Description: TIVA: General anesthesia will be based on Remifentanil and Propofol (TIVA-TCI), titrated to achieve bispectral index (BIS) between 40 and 60.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA
Description: TIVA: General anesthesia will be based on Remifentanil and Propofol (TIVA-TCI), titrated to achieve bispectral index (BIS) between 40 and 60.
Study: NCT02594163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine